Brian F Thomas

List of Publications by Year
in descending order

75 papers	3,504 citations	159358 30 h-index	143772 57 g-index
77 all docs	77 docs citations	77 times ranked	3358 citing authors

#	Article	IF	Citations
1	The Spicy Story of Cannabimimetic Indoles. Molecules, 2021, 26, 6190.	1.7	13
2	In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Biochemistry and Behavior, 2020, 193, 172918.	1.3	11
3	Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicology, 2019, 37, 17-26.	1.4	28
4	Comparison of cigarette, little cigar, and waterpipe tobacco smoke condensate and e-cigarette aerosol condensate in a self-administration model. Behavioural Brain Research, 2019, 372, 112061.	1.2	16
5	Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators. Journal of Medicinal Chemistry, 2019, 62, 9806-9823.	2.9	12
6	Diarylureas Containing 5-Membered Heterocycles as CB₁ Receptor Allosteric Modulators: Design, Synthesis, and Pharmacological Evaluation. ACS Chemical Neuroscience, 2019, 10, 518-527.	1.7	8
7	Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 414-422.	1.3	33
8	Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development. Current Topics in Medicinal Chemistry, 2019, 19, 1418-1435.	1.0	69
9	Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 437-446.	1.3	69
10	Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists. Neuropharmacology, 2018, 134, 73-81.	2.0	29
11	Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MNâ€18. Drug Testing and Analysis, 2018, 10, 137-147.	1.6	11
12	Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 162-171.	1.3	41
13	Identification of Eight Synthetic Cannabinoids, Including 5Fâ€AKB48 in Seized Herbal Products Using DARTâ€TOFâ€MS and LCâ€QTOFâ€MS as Nontargeted Screening Methods. Journal of Forensic Sciences, 2017, 62ρ.9 1151-1158.		20
14	In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicology, 2017, 35, 333-347.	1.4	35
15	Interactions of Cannabinoids With Biochemical Substrates. Substance Abuse: Research and Treatment, 2017, 11, 117822181771141.	0.5	6
16	Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution. Journal of Medicinal Chemistry, 2017, 60, 7410-7424.	2.9	21
17	The great divide: Separation between inÂvitro and inÂvivo effects of PSNCBAM-based CB 1 receptor allosteric modulators. Neuropharmacology, 2017, 125, 365-375.	2.0	23
18	Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor. Medicinal Research Reviews, 2017, 37, 441-474.	5.0	76

#	Article	IF	Citations
19	Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Substance Abuse: Research and Treatment, 2017, 11, 117822181770173.	0.5	33
20	Medullary Endocannabinoids Contribute to the Differential Resting Baroreflex Sensitivity in Rats with Altered Brain Renin-Angiotensin System Expression. Frontiers in Physiology, 2016, 7, 207.	1.3	9
21	Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry, 2016, 59, 7525-7543.	2.9	53
22	Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of inÂvivo assays in mice. Neuropharmacology, 2016, 110, 143-153.	2.0	49
23	Combination Chemistry: Structureâ€“Activity Relationships of Novel Psychoactive Cannabinoids. Current Topics in Behavioral Neurosciences, 2016, 32, 231-248.	0.8	28
24	Effect of 1-Substitution on Tetrahydroisoquinolines as Selective Antagonists for the Orexin-1 Receptor. ACS Chemical Neuroscience, 2015, 6, 599-614.	1.7	14
25	AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Î”⁹-Tetrahydrocannabinolâ€“Like Effects in Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 328-339.	1.3	110
26	Structureâ€“activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. Bioorganic and Medicinal Chemistry, 2015, 23, 2195-2203.	1.4	31
27	The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. Bioorganic and Medicinal Chemistry, 2015, 23, 5709-5724.	1.4	17
28	Potent rewarding and reinforcing effects of the synthetic cathinone 3,4â€•methylenedioxypyrovalerone (<scp>MDPV</scp>). Addiction Biology, 2014, 19, 165-174.	1.4	156
29	Diarylureas as Allosteric Modulators of the Cannabinoid CB1 Receptor: Structureâ€“Activity Relationship Studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). Journal of Medicinal Chemistry, 2014, 57, 7758-7769.	2.9	40
30	Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers. ACS Medicinal Chemistry Letters, 2014, 5, 634-638.	1.3	25
31	Substituted Tetrahydroisoquinolines as Selective Antagonists for the Orexin 1 Receptor. Journal of Medicinal Chemistry, 2013, 56, 6901-6916.	2.9	36
32	Cannabinoids in disguise: Î”9-Tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology, 2013, 75, 145-154.	2.0	94
33	Indenopyride derivative RTI-4587-073(I): A candidate for male contraception in stallions. Theriogenology, 2013, 80, 1006-1016.	0.9	17
34	The Importance of Hydrogen Bonding and Aromatic Stacking to the Affinity and Efficacy of Cannabinoid Receptor CB₂ Antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-y (SR144528). Journal of Medicinal Chemistry, 2013, 56, 6593-6612.	2.9	19
35	Analytical surveillance of emerging drugs of abuse and drug formulations. Life Sciences, 2013, 92, 512-519.	2.0	10
36	Truncated Orexin Peptides: Structureâ€“Activity Relationship Studies. ACS Medicinal Chemistry Letters, 2013, 4, 1224-1227.	1.3	18

#	Article	IF	Citations
37	Dose-Response Effects of Spectrum Research Cigarettes. Nicotine and Tobacco Research, 2013, 15, 1113-1121.	1.4	69
38	Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. Open Medicinal Chemistry Journal, 2012, 6, 1-14.	0.9	12
39	Structural analogs of pyrazole and sulfonamide cannabinoids: Effects on acute food intake in mice. European Journal of Pharmacology, 2012, 695, 62-70.	1.7	11
40	Use of SPME-HS-GC-MS for the Analysis of Herbal Products Containing Synthetic Cannabinoids. Journal of Analytical Toxicology, 2012, 36, 293-302.	1.7	32
41	Analysis of Synthetic Cannabinoids Using High-Resolution Mass Spectrometry and Mass Defect Filtering: Implications for Nontargeted Screening of Designer Drugs. Analytical Chemistry, 2012, 84, 5574-5581.	3.2	91
42	Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2980-2985.	1.0	16
43	Hijacking of Basic Research: The Case of Synthetic Cannabinoids. , 2011, 2011, .		45
44	Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacology, 2010, 210, 275-284.	1.5	37
45	Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. Chemico-Biological Interactions, 2010, 183, 317-326.	1.7	5
46	Synthesis and Biological Evaluation of Bivalent Ligands for the Cannabinoid 1 Receptor. Journal of Medicinal Chemistry, 2010, 53, 7048-7060.	2.9	62
47	Identification of [¹⁴C]Fluasterone Metabolites in Urine and Feces Collected from Dogs after Subcutaneous and Oral Administration of [¹⁴C]Fluasterone. Drug Metabolism and Disposition, 2009, 37, 1089-1097.	1.7	3
48	Cannabinoid CB1 receptor antagonists. Drug Development Research, 2009, 70, 525-526.	1.4	1
49	Neuroanatomical basis for therapeutic applications of cannabinoid receptor 1 antagonists. Drug Development Research, 2009, 70, 527-554.	1.4	5
50	Structureâ€“Activity Relationships and Conformational Freedom of CB1 Receptor Antagonists and Inverse Agonists. , 2009, , 95-119.		1
51	Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. International Review of Psychiatry, 2009, 21, 134-142.	1.4	33
52	Conformationally Constrained Analogues of N-(Piperidinyl)-5-(4-Chlorophenyl)-1-(2,4-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td (Dic Analysis, And Biological Evaluations. Journal of Medicinal Chemistry, 2008, 51, 3526-3539.	2.9	18
53	Conformational Characteristics of the Interaction of SR141716A with the CB1 Cannabinoid Receptor as Determined Through the Use of Conformationally Constrained Analogs. , 2008, , 707-718.		0
54	Physical design analysis and mainstream smoke constituent yields of the new potential reduced exposure product, Marlboro UltraSmooth. Nicotine and Tobacco Research, 2007, 9, 1197-1206.	1.4	18

#	Article	IF	Citations
55	Novel, potent THC/anandamide (hybrid) analogs. Bioorganic and Medicinal Chemistry, 2007, 15, 7850-7864.	1.4	16
56	Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs. AAPS Journal, 2006, 8, E665-E671.	2.2	15
57	Complete1H and13C assignments of fluorinated analogs of dehydroepiandrosterone. Magnetic Resonance in Chemistry, 2006, 44, 1051-1053.	1.1	5
58	Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorganic and Medicinal Chemistry, 2005, 13, 5463-5474.	1.4	27
59	Bisphenol A Exposure Causes Meiotic Aneuploidy in the Female Mouse. Current Biology, 2003, 13, 546-553.	1.8	575
60	Structure elucidation of a novel ring-constrained biaryl pyrazole CB1 cannabinoid receptor antagonist. Magnetic Resonance in Chemistry, 2003, 41, 265-268.	1.1	16
61	Structureâ€“activity relationships for 1â€²,1â€²-dimethylalkyl-Î” 8 -tetrahydrocannabinols. Bioorganic and Medicinal Chemistry, 2003, 11, 1397-1410.	1.4	38
62	Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women,,. American Journal of Clinical Nutrition, 2002, 76, 1126-1137.	2.2	162
63	Synthesis and Structureâ^'Activity Relationships of Amide and Hydrazide Analogues of the Cannabinoid CB1 Receptor Antagonist N-(Piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). Journal of Medicinal Chemistry, 2002, 45, 2708-2719.	2.9	94
64	Assessment of structural commonality between tetrahydrocannabinol and anandamide. European Journal of Pharmacology, 2002, 435, 35-42.	1.7	11
65	Quantitative analysis of the principle soy isoflavones genistein, daidzein and glycitein, and their primary conjugated metabolites in human plasma and urine using reversed-phase high-performance liquid chromatography with ultraviolet detection. Biomedical Applications, 2001, 760, 191-205.	1.7	70
66	QSAR Analysis of Î”8-THC Analogues:Â Relationship of Side-Chain Conformation to Cannabinoid Receptor Affinity and Pharmacological Potency. Journal of Medicinal Chemistry, 2000, 43, 59-70.	2.9	30
67	The Bioactive Conformation of Aminoalkylindoles at the Cannabinoid CB1 and CB2 Receptors:Â Insights Gained from (E)- and (Z)-Naphthylidene Indenes. Journal of Medicinal Chemistry, 1998, 41, 5177-5187.	2.9	60
68	Synthesis and Pharmacological Comparison of Dimethylheptyl and Pentyl Analogs of Anandamide. Journal of Medicinal Chemistry, 1997, 40, 3626-3634.	2.9	63
69	Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3Î²-(4-[125I]iodophenyl) tropan-2Î²-carboxylic acid isopropyl ester ([125I]RTM-21). Nuclear Medicine and Biology, 1996, 23, 277-284.	0.3	24
70	Structureâ^'Activity Analysis of Anandamide Analogs:Â Relationship to a Cannabinoid Pharmacophoreâ€. Journal of Medicinal Chemistry, 1996, 39, 471-479.	2.9	101
71	Determination of ibogaine in plasma by gas chromatography-chemical ionization mass spectrometry. Journal of Chromatography A, 1996, 723, 101-109.	1.8	19
72	Determination of l-Î±-acetylmethadol, l-Î±-noracetylmethadol and l-Î±-dinoracetylmethadol in plasma by gas chromatographyâ€”mass spectrometry. Biomedical Applications, 1994, 655, 201-211.	1.7	0

#	Article	IF	Citations
73	Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacology Biochemistry and Behavior, 1991, 40, 471-478.	1.3	384
74	Modification of phencyclidine intoxification and biodisposition by charcoal and other treatments. Pharmacology Biochemistry and Behavior, 1988, 30, 371-377.	1.3	6
75	Relationship between the biodisposition of [3H]soman and its pharmacological effects in mice. Toxicology and Applied Pharmacology, 1985, 80, 409-420.	1.3	49